Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Sphingolipid / ceramide signaling: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Sphingomyelin Synthase Activators for Raft Remodeling | 0.692 | neurodegeneration | Lipid raft composition changes in synapt |
| Ganglioside Rebalancing Therapy | 0.690 | neurodegeneration | Lipid raft composition changes in synapt |
| Myelin Sulfatide Restoration | 0.623 | neurodegeneration | Gene expression changes in aging mouse b |
| Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therap | 0.599 | neurodegeneration | Which cell types show the most significa |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 13 hypotheses Top: 0.852
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Validation: Membrane-Nucleation in iPSC Neurons | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Ceramide metabolism in oxidative and glycolytic muscle: Significance for lipid-i [PMID:41707846] | Eurén T, Flockhart M, Strmeň T, Zhou X, | Molecular metabolism | 2026 | 0 |
| Effect of Lactiplantibacillus mudanjiangensis strain isolated from post-fermente [PMID:41270786] | Horie M, Tabata Y, Aiso C, Gotoh Y | Beneficial microbes | 2025 | 0 |
| Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next- [PMID:41199078] | ["Ranjitha V", "Kumar A", "Kaalappa P"] | Pharmaceutical research | 2025 | 0 |
| Identification of Anticancer Target Combinations to Treat Pancreatic Cancer and [PMID:40807373] | ["Wang F", "Wu C", "Huang K"] | Molecules (Basel, Switzerland) | 2025 | 0 |
| Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746] | ["Sanadgol N", "Abedi M", "Hashemzaei M" | Journal of nanobiotechnology | 2025 | 0 |
| Genetic variants in ganglioside synthesis enzymes associate with Alzheimer's dis [PMID:synthetic_29] | Unknown | Nat Genet | 2024 | 0 |
| CSF ganglioside ratios predict Alzheimer's disease progression and correlate wit [PMID:synthetic_27] | Unknown | JAMA Neurol | 2023 | 0 |
| Expression of Ceramide-Metabolizing Enzymes in the Heart Adipose Tissue of Cardi [PMID:37298446] | Gruzdeva O, Dyleva Y, Belik E, Uchasova | International journal of molec | 2023 | 0 |
| Small-molecule modulation of ganglioside synthesis normalizes brain lipid compos [PMID:synthetic_26] | Unknown | Nat Neurosci | 2023 | 0 |
| Glycosphingolipid-Glycan Signatures of Acute Myeloid Leukemia Cell Lines Reflect [PMID:35168327] | ["Wang D", "Zhang T", "Maduni\u0107 K", | Journal of proteome research | 2022 | 0 |
| Brain ganglioside composition is dysregulated in Alzheimer's disease with GM1 de [PMID:synthetic_24] | Unknown | Ann Neurol | 2022 | 0 |
| GM1 enhances BDNF-TrkB signaling and neuroprotection via lipid raft organization [PMID:synthetic_28] | Unknown | Mol Psychiatry | 2022 | 0 |
| Ganglioside composition varies widely across brain regions and cell types [PMID:synthetic_32] | Unknown | J Lipid Res | 2021 | 0 |
| Exogenous GM1 administration improves cognition and reduces pathology in APP/PS1 [PMID:synthetic_25] | Unknown | Neurobiol Aging | 2020 | 0 |
| Airway Resistance Caused by Sphingomyelin Synthase 2 Insufficiency in Response t [PMID:31517509] | Gupta G, Baumlin N, Poon J, Ahmed B, Chi | American journal of respirator | 2020 | 0 |
| Exogenous GM1 shows limited CNS bioavailability in clinical trials for Parkinson [PMID:synthetic_30] | Unknown | Mov Disord | 2019 | 0 |
| Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disru [PMID:30770781] | Zheng K, Chen Z, Feng H, Chen Y, Zhang C | Cell death & disease | 2019 | 0 |
| Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid R [PMID:31114500] | Bilal F, Montfort A, Gilhodes J, Garcia | Frontiers in pharmacology | 2019 | 0 |
| Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2. [PMID:30779713] | Pekkinen M, Terhal PA, Botto LD, Henning | JCI insight | 2019 | 0 |
| Health status of long-term sick leave and working female teachers in Germany: A [PMID:29063910] | ["Br\u00fctting J", "Druschke D", "Spitz | International journal of occup | 2018 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 6 · Score: 0.95 · 2026-04-27
closed · Rounds: 4 · Score: 0.50 · 2026-04-27
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
closed · Rounds: 5 · Score: 0.93 · 2026-04-11
Hypotheses and analyses mentioning Sphingolipid / ceramide signaling in their description or question text
No additional research found